Ljungman P, Biron P, Bosi A, Cahn J Y, Goldstone A H, Gorin N C, Link H, Messina C, Michallet M, Richard C
Department of Medicine, Huddinge University Hospital, Sweden.
Bone Marrow Transplant. 1994 Feb;13(2):209-12.
CMV pneumonia is rare following ABMT. No information has been presented concerning risk factors or outcome of antiviral therapy. Information concerning CMV pneumonia after ABMT was collected from bone marrow transplant centers in Europe. Twenty-one patients who fulfilled the diagnostic criteria of CMV pneumonia were reported. Eighteen of these patients were reported from centers who also reported the total number of ABMT performed. The CMV pneumonia frequency among 2252 reported ABMT patients was 0.8%, and this varied from 0% to 8.6% between different centers. Survival for > 30 days from diagnosis of pneumonia was 43%. Three patients suffered relapses, which were fatal, giving a total survival of 28%. Patients treated with or without TBI had a survival of 18% and 50%, respectively. Among patients given ganciclovir or foscarnet with or without intravenous immune globulin, survival at 30 days was 50% and total survival 28%. There was no difference in survival with or without the addition of intravenous immune globulin. CMV pneumonia is an infrequent but serious complication of ABMT.
巨细胞病毒肺炎在自体骨髓移植后较为罕见。目前尚未有关于抗病毒治疗的危险因素或结果的相关信息。关于自体骨髓移植后巨细胞病毒肺炎的信息是从欧洲的骨髓移植中心收集的。报告了21例符合巨细胞病毒肺炎诊断标准的患者。其中18例患者来自那些也报告了自体骨髓移植总数的中心。在报告的2252例自体骨髓移植患者中，巨细胞病毒肺炎的发生率为0.8%，不同中心之间的发生率从0%到8.6%不等。从肺炎诊断起存活超过30天的比例为43%。3例患者复发，均为致命性复发，总体生存率为28%。接受或未接受全身照射的患者生存率分别为18%和50%。在接受更昔洛韦或膦甲酸钠治疗且使用或未使用静脉注射免疫球蛋白的患者中，30天生存率为50%，总体生存率为28%。添加或不添加静脉注射免疫球蛋白的生存率无差异。巨细胞病毒肺炎是自体骨髓移植一种不常见但严重的并发症。
